Temozolomide radiochemotherapy for high-grade glioma patients with hemodialysis: a case series of 7 patients.

Jun MutoTomoo MatsutaniRyosuke MatsudaMasashi KinoshitaMitsuteru OikawaJohan PalludHikaru Sasaki

Published in: Neuro-oncology practice (2019)

Decreasing the dose of TMZ might not be required in HD patients with high-grade gliomas during concomitant radiochemotherapy and maintenance therapy. However, careful clinical and hematological observation is required to avoid critical hematotoxicity and infection.

Keyphrases

high grade
end stage renal disease
low grade
chronic kidney disease
newly diagnosed
peritoneal dialysis
ejection fraction
locally advanced
prognostic factors
squamous cell carcinoma
patient reported outcomes
mesenchymal stem cells
radiation therapy